JPRN-UMIN000062223 On-screen Gaze Feedback Perceptual Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a specific protocol into a decision-ready landscape. This report examines JPRN-UMIN000062223—Effects of on-screen gaze feedback on eye movements in children—with PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Recheck the live record before operational decisions.

Why this trial is differentiated

JPRN-UMIN000062223 tests On-screen Gaze Feedback in Perceptual Disorders. Unlike asset-only screens, this protocol highlights how intervention delivery, endpoint choice, enrollment and execution setting can create clinical white space. The study is indexed as Phase 2 with 開始前/Preinitiation status.

Trial landscape table

Design and endpoint interpretation

Allocation is 非ランダム化/Non-randomized, masking is オープン/Open -no one is blinded, and the intervention model is 単群/Single arm. The primary endpoint—視線フィードバック前後におけるNSUCOスコア（ability、accuracy、head movement、body movement）の変化。介入前後のスコアを比較する。—defines the uncertainty this study can resolve. Enrollment of 20 and geography in Japan influence precision, feasibility and external validity.

Benchmark and readout context

PatSnap Clinical Trial Result records provide structured endpoint benchmarks for adjacent programs. For procedure-led, behavioral or device-like interventions, direct cross-trial comparisons may be especially fragile because technique, operator experience, baseline severity and assessment schedules differ. The appropriate benchmark is therefore the endpoint architecture and clinically meaningful effect threshold, not a single headline number.

Build a living monitor: connect to PatSnap MCP Servers to track protocol amendments, completion dates and newly indexed results.

Asset and sponsor context

Drug & Asset context: On-screen Gaze Feedback is the protocol intervention. No separate normalized investigational-drug entity is required where the program is procedure-, device-, behavioral- or care-pathway-led; this distinction prevents false asset attribution.

Company & Deal Intelligence context: University of Tokushima — http://www.tokushima-u.ac.jp.

Sponsor capability still matters: multicenter reach, intervention standardization, operator training, data quality and confirmatory funding determine whether a signal becomes transferable evidence.

White space

• Standardization: reproducible intervention delivery across sites and operators.
• Patient selection: prospective criteria identifying the population most likely to benefit.
• Clinical meaning: endpoints tied to symptoms, function, recurrence, treatment burden or quality of life.
• Durability: follow-up long enough to distinguish transient change from lasting benefit.
• External validity: evidence across additional geographies and real-world settings.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, readout timing, first result indexing and sponsor partnerships. For a focused trial, a change in technique or endpoint can be as consequential as the final data release.

Bottom line

JPRN-UMIN000062223 provides a specific view of Perceptual Disorders development through On-screen Gaze Feedback. Its strategic value will depend on whether the design produces clinically meaningful, reproducible and operationally credible evidence.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence in an SEO-ready workflow.